Stem Cell Therapeutics Provides Corporate Update
25 July 2013 - 9:00PM
Marketwired Canada
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical
company developing cancer stem cell-related therapeutics, today provided the
following corporate update:
-- Safety and pharmacokinetic data from studies in rodents and non-human
primates, using several variants of the company's high-affinity CD47
antagonist, are expected to become available in the third quarter. Stem
Cell Therapeutics (SCT) has chosen to target the CD47 protein using a
modified version of its natural ligand, SIRPa, fused to an
immunoglobulin Fc region. The fusion protein has similar pharmacological
properties to a traditional monoclonal antibody and other Fc fusion
proteins on the market and in development. However, the SIRPaFc protein
appears to have distinct binding properties compared to those of many
anti-CD47 monoclonal antibodies. The safety data expected in the third
quarter, combined with a large body of existing efficacy data, will
direct the company's selection of a definitive clinical development
candidate. A formal IND-enabling program is expected to commence shortly
thereafter.
-- Dosing in a Phase I multicenter dose-escalation study (50mg-350mg) with
tigecycline in patients with relapsed or refractory acute myeloid
leukemia (AML) is also expected to be completed in the third quarter.
The program is based on Dr. Aaron Schimmer's discovery that tigecycline,
an FDA-approved antibiotic, selectively targets leukemia cells and
leukemic stem cells by inhibiting mitochondrial protein synthesis and
thus shutting down the cells energy supply. The upcoming data will guide
the design of a Phase II trial projected to commence in 2014. In
parallel, the company and its collaborators are actively investigating
improved formulations and novel analogues of tigecycline, efforts which
are central to the commercialization of this technology.
-- The company is continuing its ongoing dialogues with third parties
regarding partnerships and collaborations on several of its internal
programs, as well as its discussions related to the in-licensing of
additional cancer stem cell assets. SCT anticipates being in a position
to provide more details on these efforts by year end.
-- The company is in the process of ceasing all activities associated with
its pre-merger historic regenerative neurology programs and anticipates
completing this in the third quarter. Moving forward all resources will
be focused on the company's promising cancer stem cell programs. While
SCT will attempt to monetize its intellectual property underpinning the
legacy programs, the company has determined that doing so through the
joint venture previously contemplated is not a viable option.
-- SCT has initiated several efforts to amplify and broaden its visibility
in a cost-effective way. These range from strengthening its Board of
Directors and developing relationships with additional key opinion
leaders in the cancer stem cell field, to working with investor relation
firms and capital markets advisors, such as the recently announced
appointment of ProActive Capital Group to assist in increasing awareness
of the company among investors.
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. (SCT) is a biopharmaceutical company dedicated to
advancing cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and groundbreaking
Canadian stem cell research, the company is supported by established links to a
group of Toronto academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research hubs. SCT's
clinical stage programs include the recently in-licensed program focused on the
structure of tigecycline, which is currently being evaluated in a multi-centre
Phase I study in patients with acute myeloid leukemia (AML), as well as
TTI-1612, a non-stem cell asset being tested in a 28-patient Phase I trial in
interstitial cystitis ("IC") patients, which is near completion. The Company
also has two premier preclinical programs, SIRPaFc and a CD200 monoclonal
antibody (mAb), which target two key immunoregulatory pathways that tumor cells
exploit to evade the host immune system. SIRPaFc is an antibody-like fusion
protein that blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is a fully
human monoclonal antibody that blocks the activity of CD200, an
immunosuppressive molecule that is overexpressed by many hematopoietic and solid
tumors. For more information, visit www.stemcellthera.com.
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com
Investor Contact: ProActive Capital
Jeff Ramson
(646) 863-6341
jramson@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sunvest Minerals Corp (TSX Venture Exchange): 0 recent articles
More Stem Cell Therapeutics Corp. News Articles